Professor Jin Li & Professor Joon Oh Park: Carrying the Torch Forward with Unity and Collaboration — FACO as a Platform for Advancing Comprehensive Academic Cooperation and the Joint Progress of Asian Clinical Oncology
Editor’s Note: The 13th Federation of Asian Clinical Oncology (FACO) Annual Meeting was grandly held in Shanghai on October 24–25, 2025. As a collaborative organization jointly initiated by the…
ISEH 2025 | Harvesting the Fruits of Collaboration: China–Japan Symposium on Stem Cells and Cell Therapy Opens a New Chapter
Editor’s Note: As autumn scents the air with osmanthus blossoms, leading scientists gathered in Kumamoto for an intellectual feast. The 54th Annual Scientific Meeting of the International Society for Experimental…
ESMO Global Insight | Professor Andrea Necchi: Disitamab Vedotin Plus Immunotherapy Nearly Doubles Overall Survival in Advanced HER2-Expressing Urothelial Carcinoma
The combination of antibody–drug conjugates (ADCs) with immunotherapy has delivered major breakthroughs across several tumor types, including urothelial carcinoma. At the 2025 European Society for Medical Oncology (ESMO) Congress, results from a pivotal Phase III trial (LBA7) were presented showing that the HER2-targeted ADC disitamab vedotin, combined with the PD-1 inhibitor toripalimab, nearly doubled overall survival compared with chemotherapy as first-line treatment for patients with HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC). This novel regimen, centered on an innovative ADC, may redefine first-line therapy—though several key questions remain.
Highlights from the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025)
At the recent FACO 2025 Conference held in Shanghai, Dr. Joon Oh Park, President of KSMO and President-elect of FACO, shared his perspectives on the evolving landscape of cancer treatment…
ESMO China Voice | Professor Jiesong Wang: The iPET-NCCN-IPI Model May Optimize Risk Stratification in Diffuse Large B-Cell Lymphoma
Editor’s Note: The 2025 European Society for Medical Oncology (ESMO) Annual Congress was grandly held in Berlin, marking another milestone in global oncology research. In the field of hematologic malignancies,…
ESMO China Voice | Dr. Sicong Zhang: Refractory DLBCL Patients Share Similar Immune Signatures
The European Society for Medical Oncology (ESMO) Congress 2025 was grandly held in Berlin, marking another wave of scientific innovation across the field of oncology.In hematology, several exciting advances drew attention—from uncovering the mechanisms of CAR-T resistance and exploring dual-target immunotherapies, to studies on precision treatment discontinuation in multiple myeloma and single-cell immune atlas mapping that deepens our understanding of hematologic malignancies. Together, these studies highlight continuous innovation in medical science and bring new hope for improving diagnosis and treatment in hematologic diseases.To further focus on major breakthroughs in hematology and foster academic exchange, Oncology Frontier – Hematology News invited Dr. Sicong Zhang, from Professor Huilai Zhang’s research group at Tianjin Medical University Cancer Institute and Hospital, to discuss the innovation and clinical significance of a new study presented at ESMO 2025, as well as to share his insights into future trends in the field.
ESMO China Voice | Dr. Cong Sun: Grade 3B Follicular Lymphoma Is an Independent Risk Factor Affecting Both PFS and OS
Editor’s Note: The 2025 European Society for Medical Oncology (ESMO) Annual Congress was grandly held in Berlin, marking another wave of major scientific breakthroughs in oncology. In the field of…
ESMO China Voice | Prof. Liang Wang: CD19/CD22 Bispecific CAR-T Therapy Demonstrates Remarkable Efficacy and Safety in R/R LBCL
In hematology, this year’s highlights encompassed several cutting-edge research directions—from unraveling the mechanisms of CAR-T resistance and exploring dual-target immunotherapies that may enhance precision and efficacy, to studies on treatment-free remission in multiple myeloma, and the creation of single-cell immune atlases offering novel insights into hematologic disease mechanisms. These achievements collectively reflect the continued progress and innovation in biomedical science and bring new hope for patients with hematologic malignancies.
13th FACO Annual Academic Conference Grandly Held in Shanghai! Leading Experts from China, Japan, and South Korea Gather to Foster Clinical Oncology
Editor’s Note: Promoting collaboration through exchange, and seeking mutual success through cooperation — on October 24, 2025, the 13th Federation of Asian Clinical Oncology (FACO) Annual Conference was grandly held…